Legend Biotech (LEGN) Total Liabilities (2019 - 2026)
Legend Biotech's (LEGN) quarterly Total Liabilities came in at $629.0 million in Q1 2026, up 5.2% YoY from $597.9 million in Q1 2025, and down 14.02% on a QoQ basis from $731.6 million in Q4 2025.
Legend Biotech (LEGN) Total Liabilities (2019 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 8 years of Total Liabilities data on file, last reported at $629.0 million in Q1 2026.
- Quarterly Total Liabilities rose 5.2% year-over-year to $629.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $629.0 million (up 5.2% YoY) and the FY2025 annual result came in at $731.6 million, up 16.2% from the prior year.
- Total Liabilities retreated to $629.0 million in Q1 2026, from $731.6 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $731.6 million in Q4 2025 to a low of $499.7 million in Q3 2023.
- A 5-year average of $612.0 million and a median of $611.0 million in 2024 frame the typical range for Total Liabilities.
- The widest YoY moves for Total Liabilities: up 65.95% in 2022, down 99.85% in 2022.
- Tracing LEGN's Total Liabilities over 5 years: stood at $586.7 million in 2022, then increased by 1.8% to $597.2 million in 2023, then grew by 5.42% to $629.6 million in 2024, then increased by 16.2% to $731.6 million in 2025, then retreated by 14.02% to $629.0 million in 2026.
- The last three Total Liabilities figures came in at $629.0 million (Q1 2026), $731.6 million (Q4 2025), and $701.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | 521.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 521.30 Mn |
| Mar 31, 2026 | 629.00 Mn |
| Dec 31, 2025 | 731.60 Mn |
| Sep 30, 2025 | 701.69 Mn |
| Jun 30, 2025 | 654.38 Mn |
| Mar 31, 2025 | 597.90 Mn |
| Dec 31, 2024 | 629.60 Mn |
| Sep 30, 2024 | 619.72 Mn |
| Jun 30, 2024 | 639.18 Mn |
| Mar 31, 2024 | 611.05 Mn |
| Dec 31, 2023 | 597.24 Mn |
| Sep 30, 2023 | 499.70 Mn |
| Jun 30, 2023 | 523.63 Mn |
| Mar 31, 2023 | 556.20 Mn |
| Dec 31, 2022 | 586.65 Mn |
| Mar 31, 2022 | 601.95 Mn |
| Dec 31, 2021 | 353.52 Mn |
| Sep 30, 2021 | 587.90 Mn |
| Jun 30, 2021 | 535.21 Mn |
| Mar 31, 2021 | 408.80 Bn |